# Targeting CB1 and TRPM8 Receptors to Counteract CD8+ T Cell Exhaustion > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cb1-receptor-antagonist-cancer-immunotherapy/ > **Published:** 2026-04-11T03:06:44-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:25:22-04:00 > **Clinical Summary:** Explore how cb1 receptor antagonist cancer immunotherapy may reduce CD8+ T cell exhaustion and improve immune response in cancer treatment. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. 🔬 Evidence Watch  |  CED Clinic CancerImmunotherapyCb1T-CellsClinical Study Journal Scientific reports Study Type Clinical Study Population Human participants Why This Matters T cell exhaustion is a major barrier to effective cancer immunotherapy, with exhausted CD8+ T cells unable to mount robust anti-tumor responses. This study provides initial evidence that cannabinoid receptor modulation may influence immune checkpoint expression on these critical immune cells. Clinical Summary This clinical study examined how CB1 antagonism (AM251), TRPM8 antagonism (RQ-00203078), and PI3K inhibition (alpelisib) affect exhaustion markers on CD8+ T cells in human participants. CB1 antagonist treatment, alone or combined with alpelisib, significantly reduced expression of exhaustion markers PD-1 and Lag-3 on CD8+ T cells. Conversely, TRPM8 antagonism increased PD-1 expression. The study suggests differential roles for these receptors in regulating T cell functional states within cancer-related inflammatory contexts. Dr. Caplan’s Take “While intriguing mechanistically, this early-stage work requires substantial replication and safety data before clinical application. The opposing effects of CB1 versus TRPM8 modulation on immune function highlight the complexity of cannabinoid system interactions with cancer immunity.” Clinical Perspective 🧠 Clinicians should view this as foundational research rather than immediately actionable data. Patients using cannabis during cancer treatment should discuss potential immune system interactions with their oncology team, though current evidence remains insufficient to guide specific recommendations about cannabinoid use and immunotherapy timing. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Targeting%20CB1%20and%20TRPM8%20receptors%20to%20counteract%20CD8%2B%20T%20cell%20exhaustion.%20%40drcaplan&url=https%3A//pubmed.ncbi.nlm.nih.gov/41963448/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//pubmed.ncbi.nlm.nih.gov/41963448/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Targeting%20CB1%20and%20TRPM8%20receptors%20to%20counteract%20CD8%2B%20T%20cell%20exhaustion.%20--%20via%20%40drcaplan.bsky.social%20https%3A//pubmed.ncbi.nlm.nih.gov/41963448/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://pubmed.ncbi.nlm.nih.gov/41963448/](https://pubmed.ncbi.nlm.nih.gov/41963448/) Table of Contents - [FAQ](#FAQ)[How does blocking CB1 receptors affect cancer-fighting T cells?](#How_does_blocking_CB1_receptors_affect_cancer-fighting_T_cells) - [Could cannabis use interfere with cancer immunotherapy effectiveness?](#Could_cannabis_use_interfere_with_cancer_immunotherapy_effectiveness) - [What is the significance of combining CB1 antagonists with existing cancer drugs?](#What_is_the_significance_of_combining_CB1_antagonists_with_existing_cancer_drugs) - [How does TRPM8 receptor targeting differ from CB1 in cancer treatment?](#How_does_TRPM8_receptor_targeting_differ_from_CB1_in_cancer_treatment) - [What are the clinical limitations of this cannabis-related cancer research?](#What_are_the_clinical_limitations_of_this_cannabis-related_cancer_research) - [Related](#Related) ## FAQ #### How does blocking CB1 receptors affect cancer-fighting T cells? This study found that using a CB1 receptor antagonist (AM251) significantly reduced the expression of exhaustion markers PD-1 and Lag-3 on CD8+ T cells. This suggests that blocking CB1 receptors may help prevent T cell exhaustion and maintain their cancer-fighting ability. #### Could cannabis use interfere with cancer immunotherapy effectiveness? Based on this research, cannabis activation of CB1 receptors might potentially contribute to T cell exhaustion, which could theoretically reduce immune system effectiveness against tumors. However, this is early-stage research and clinical implications for cannabis patients undergoing immunotherapy remain unclear. #### What is the significance of combining CB1 antagonists with existing cancer drugs? The study showed that combining the CB1 antagonist AM251 with alpelisib (a PI3K inhibitor used in breast cancer) enhanced the reduction of T cell exhaustion markers. This suggests potential synergistic effects that could improve cancer immunotherapy outcomes. #### How does TRPM8 receptor targeting differ from CB1 in cancer treatment? Unlike CB1 antagonism, blocking TRPM8 receptors with RQ-00203078 actually increased PD-1 expression on CD8+ T cells, suggesting it may worsen T cell exhaustion. This indicates that TRPM8 and CB1 receptors have opposite effects on immune function in the cancer context. #### What are the clinical limitations of this cannabis-related cancer research? This study is classified as “monitored relevance” early-stage research requiring further evidence before clinical action. The findings are preliminary and need validation in human [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) before any recommendations can be made about [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in cancer patients. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Opioids and Cannabis: An Uncertain Combination?](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) Explore the complex interactions between opioids and cannabis, relevant for understanding [cannabinoid effects](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) on immune function. [Read More](https://cedclinic.com/opioid-cannabis-interactions-risks-clinical-insights/) [Cannabis Use Disorder Treatment Europe Review](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) Review current evidence on [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) treatments, providing context for [cannabinoid receptor research](https://cedclinic.com/cannabis-reinforcement-and-dependence-cb1-receptors/). [Explore Now](https://cedclinic.com/cannabis-use-disorder-treatment-europe-evidence-watch/) [The Best CBD for Immune Support and Daily Resilience in 2026 | stupidDOPE | Est. 2008](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) Discover top CBD options for immune support, complementing research on cannabinoid receptor modulation in immune cells. [Learn More](https://cedclinic.com/the-best-cbd-for-immune-support-and-daily-resilience-in-2026-stupiddope-est-2008/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).